Pyxis Oncology Inc (PYXS) Stock Price, Quote & News

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 453 3596

Website: www.pyxisoncology.com

Address:

321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States

OfficialStocktwitsUser Feb. 21 at 5:55 PM

$PYXS RSI: 48.10, MACD: -0.1358 Vol: 0.10, MA20: 1.47, MA50: 1.84 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

WoodnighthawkFund Feb. 18 at 4:19 PM

$PYXS Pyxis Oncology is an early-stage biotech with platform risk. Clinical validation is required for rerating. Cash runway defines downside.

0 · Reply

MadCall911 Feb. 17 at 9:14 PM

$MNDR Solid AH play. It is just getting started. $OLB $PYXS $ATOM

0 · Reply

MarketJunction Feb. 17 at 3:22 PM

$PYXS Pyxis Oncology develops antibody-drug conjugates for cancer, with early-stage pipeline and binary clinical catalysts ahead.

0 · Reply

RadioIsotope25 Feb. 13 at 3:33 PM

Why radiopharmaceuticals are becoming central to precision oncology $RADX $AKTS $CHRS $PYXS https://www.drugtargetreview.com/article/192528/why-radiopharmaceuticals-are-becoming-central-to-precision-oncology/

0 · Reply

RadioIsotope25 Feb. 9 at 5:29 PM

$PYXS ChatGPT says interim CEO’s incentive is geared towards strategic transactions. Therefore with 28% discontinuation rate this will be a vehicle for a reverse merger.

1 · Reply

RadioIsotope25 Feb. 6 at 7:02 PM

$PYXS Ceo left Pyxis - that’s a major red flag 🚩

1 · Reply

jiam Feb. 6 at 3:08 PM

$PYXS is quiet here...

0 · Reply

RadioIsotope25 Feb. 6 at 2:34 PM

$RADX Last two $LNTH acquisitions have been averaged $350 million. They own 15% of RADX and they have a plug and play brain mets Phase2b radio imaging asset preparing for a phase3 (would be #3 biggest radio imaging agent globally behind Telix and Lantheus two leaders I. Prostate) + they have a pipeline full of designer radiopharmaceuticals and more on the way from MD Anderson. At $60 million market cap you do the math. $IMNM $PYXS $IBRX

0 · Reply

OfficialStocktwitsUser Feb. 3 at 4:14 PM

$PYXS RSI: 36.49, MACD: -0.2124 Vol: 0.19, MA20: 1.65, MA50: 2.62 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Dec 19, 2025, 9:07 AM EST - 2 months ago

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Dec 18, 2025, 2:57 PM EST - 2 months ago

Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript

Dec 18, 2025, 7:00 AM EST - 2 months ago

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Nov 3, 2025, 4:05 PM EST - 4 months ago

Pyxis Oncology to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 4 months ago

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 13, 2025, 4:05 PM EDT - 4 months ago

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Oct 9, 2025, 7:30 AM EDT - 4 months ago

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Sep 30, 2025, 4:24 PM EDT - 5 months ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 21, 2025, 7:30 AM EDT - 6 months ago

Pyxis Oncology to Participate in September Investor and Industry Conferences

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:00 AM EDT - 10 months ago

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 7:30 AM EDT - 10 months ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Apr 25, 2025, 1:17 PM EDT - 10 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 2, 2025, 7:30 AM EDT - 11 months ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 18, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 4, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Dec 19, 2024, 4:08 PM EST - 1 year ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Dec 7, 2024, 1:30 AM EST - 1 year ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Nov 21, 2024, 9:18 AM EST - 1 year ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 20, 2024, 4:05 PM EST - 1 year ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 8, 2024, 1:30 PM EST - 1 year ago

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Sep 13, 2024, 7:08 AM EDT - 1 year ago

Moment Of Truth Approaches For Pyxis Oncology

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

May 30, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 9, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Mar 27, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 21, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 7, 2024, 4:30 PM EST - 2 years ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 5, 2024, 4:45 PM EST - 2 years ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Nov 7, 2023, 4:30 PM EST - 2 years ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Sep 27, 2023, 9:18 AM EDT - 2 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Sep 7, 2023, 8:09 AM EDT - 2 years ago

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Aug 31, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 23, 2023, 8:35 AM EDT - 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 10, 2023, 2:56 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Jul 10, 2023, 3:01 AM EDT - 2 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 12, 2023, 2:59 AM EDT - 2 years ago

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

OfficialStocktwitsUser Feb. 21 at 5:55 PM

0 · Reply

WoodnighthawkFund Feb. 18 at 4:19 PM

$PYXS Pyxis Oncology is an early-stage biotech with platform risk. Clinical validation is required for rerating. Cash runway defines downside.

0 · Reply

MadCall911 Feb. 17 at 9:14 PM

$MNDR Solid AH play. It is just getting started. $OLB $PYXS $ATOM

0 · Reply

MarketJunction Feb. 17 at 3:22 PM

$PYXS Pyxis Oncology develops antibody-drug conjugates for cancer, with early-stage pipeline and binary clinical catalysts ahead.

0 · Reply

RadioIsotope25 Feb. 13 at 3:33 PM

0 · Reply

RadioIsotope25 Feb. 9 at 5:29 PM

$PYXS ChatGPT says interim CEO’s incentive is geared towards strategic transactions. Therefore with 28% discontinuation rate this will be a vehicle for a reverse merger.

1 · Reply

RadioIsotope25 Feb. 6 at 7:02 PM

$PYXS Ceo left Pyxis - that’s a major red flag 🚩

1 · Reply

jiam Feb. 6 at 3:08 PM

$PYXS is quiet here...

0 · Reply

RadioIsotope25 Feb. 6 at 2:34 PM

0 · Reply

OfficialStocktwitsUser Feb. 3 at 4:14 PM

0 · Reply

LabPsycho Feb. 3 at 3:24 PM

$PYXS Looks like it could trade 1.5 - 2 million shares today. Wild, baseless guess here but I wonder if that run from $1 to over $2 a few weeks ago was in part due not only to January bounce but my guess is some folks already knew a new and improved CEO was on the way? Rebuttals?

1 · Reply

LabPsycho Feb. 3 at 1:40 PM

$PYXS New CEO: Mr. Civik most recently served as President and Chief Executive Officer of Five Prime Therapeutics, where he led the company through its acquisition by Amgen for $1.9 billion in April 2021. He most recently served as Chairperson of the Board of ImCheck Therapeutics and Repare Therapeutics, providing strategic and governance oversight, including through their respective acquisitions by Ipsen and XOMA.

1 · Reply

StockConsultant Feb. 3 at 1:23 PM

$PYXS Pyxis Oncology stock watch, low volume pullback to 1.51 support area with high trade quality at https://stockconsultant.com/?PYXS

0 · Reply

LabPsycho Feb. 2 at 3:23 PM

$PYXS If one can roughly visualize the sinusoidal movements of stocks as a Fourier Transform in their mind's eye and how they may breath, one might be tempted to speculate PYXS has finished exhaling and possibly prepping for a climb back to $1.80. I can not find the post but a while back I thought a reasonable target was $1.80 +/- 40% by April. Not quite the 40% retrace from 1.80 so we'll see.

0 · Reply

GJ_Rockabilt Jan. 30 at 4:26 PM

$PYXS Today is last day to sign up for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

peepthestamp Jan. 24 at 7:25 AM

$PYXS

0 · Reply

RadioIsotope25 Jan. 21 at 4:16 PM

$RADX Big time winner $SMMT $IMNM $PYXS

0 · Reply

ElonRMusk Jan. 20 at 2:06 PM

$PYXS oh boy. Markets are gonna be red today. Looks like its a phone down kind of day, pick things up later this week

0 · Reply

LabPsycho Jan. 18 at 3:14 PM

$PYXS @marin_binzari I don't agree...there are some newly minted bag holders above this price = resistance IMO. $2.36 may be a ways off.

2 · Reply

ElonRMusk Jan. 16 at 7:40 PM

$PYXS that was wild! Someone dropped 300-400k shares instantly.

1 · Reply

marin_binzari Jan. 16 at 3:09 PM

$PYXS a little pull back testing 1.91, and then 2. 36, target, not safe play target 3.2 😅

0 · Reply

ElonRMusk Jan. 16 at 12:12 AM

$PYXS added $1.82

0 · Reply

Market Cap	88.42M
Revenue (ttm)	16.15M
Net Income (ttm)	-77.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-478.82%
Debt to Equity Ratio	0.00

Volume	248,300
Avg Vol	1,342,882
Day's Range	N/A - N/A
Shares Out	62.26M
Stochastic %K	67%
Beta	1.45
Analysts	Strong Sell
Price Target	$6.92